117
Views
0
CrossRef citations to date
0
Altmetric
Inflammatory diseases

Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: Interim results of a single-arm, open-label study

, , , , , & show all
Pages 103-108 | Received 01 Jun 2010, Accepted 08 Jun 2010, Published online: 22 Jan 2011

References

  • Traub M, Marshall K. Psoriasis – Pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev. 2007;12(4):319–330.
  • Lebwohl M. A clinician's paradigm in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(1 suppl 1):S59–S69.
  • Shear NH. Fulfilling an unmet need in psoriasis. Do biologicals hold the key to improved tolerability? Drug Safety. 2006;29(1):49–66.
  • Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J, Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029–4038.
  • Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM, Lee FY. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol. 2009;60(2):225–230.
  • Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144(12):1571–1575.
  • Ortonne JP. Clinical response to alefacept: Results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17(suppl 2):12–16.
  • Krueger G. Clinical response to alefacept: Results of a phase 3 study of intervenous administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2003;17(suppl 2):17–24.
  • Biogen Briefing Document. FDA Dermatology Advisory Meeting, Bethesda, MD, May 2002. Available from: http://www. Fda.gov/ohrms/dockets/ac/02/briefing/3865B1_01_Biogen.pdf.
  • Cooper JC, Morgan G, Harding S, Subramanyam M, Majeau GR, Moulder K, Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol. 2003;33(3):666–675.
  • Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol. 2003;49:816–825.
  • Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719–727.
  • Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2003;2:624–628.
  • Elder JT. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun. 2009;10(3):201–209.
  • Eyre RW, Krueger GG. Response to injury of skin involved and uninvolved with psoriasis, and its relation to disease activity: Koebner and ‘reverse’ Koebner reactions. Br J Dermatol. 1982;106(2):153–159.
  • Grekin DA, Van Scott EJ. Dermal role and controls in psoriasis. Arch Dermatol. 1973;108:425.
  • Dellon AL. Case report: Long-term remission of psoriasis after dermatome shaving. Plast Reconstr Surg. 1982;70:220–226.
  • Martin JM, Conde A, Pinazo I, García L, Sánchez AL, Pinazo J, Reverse koebnerization after radiotherapy in a woman with a mastectomy for breast carcinoma. J Am Acad Dermatol. 2006;55(5):S90–S91.
  • Weiss G, Shemen A, Trau H. The koebner phenomenon: Review of the literature. J Eur Acad Dermatol Venereol. 2002;16:241–248.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.